Bayer has agreed to acquire Perfuse Therapeutics in a deal that includes $300 million upfront and up to $2.15 billion in potential milestone payments. The acquisition gives the German drugmaker access to an experimental ocular implant that showed promising results in mid-stage clinical trials last year.
Based in San Francisco, Perfuse Therapeutics is developing PER-001, an intravitreal implant designed to deliver an endothelin receptor antagonist directly into the eye. The therapy targets endothelin-1, a molecule known to constrict blood vessels and found at elevated levels in conditions such as glaucoma, diabetic retinopathy and age-associated macular degeneration. By inhibiting this pathway, the implant aims to enhance retinal blood flow and reduce cell damage associated with these diseases.
Bayer sees PER-001 as a strategic addition to its ophthalmology portfolio. The company currently markets Eylea in Europe through a partnership with Regeneron Pharmaceuticals, using the therapy to treat multiple eye conditions. Eylea remains Bayer’s top-selling product, generating approximately $3.7 billion in revenue last year.
However, with Eylea approaching the later stages of its lifecycle and experiencing declining sales, Bayer has been seeking a successor within its pipeline. While its subsidiary BlueRock Therapeutics initiated an early-stage study targeting photoreceptor diseases, much of Bayer’s late-stage development focus lies outside ophthalmology, particularly in oncology and cardiovascular and renal conditions.
The acquisition of Perfuse Therapeutics provides Bayer with a more advanced candidate in eye disease. Phase 2 studies of PER-001 in glaucoma and diabetic retinopathy primarily assessed safety but also produced early signals suggesting potential improvements in vision.
At the time those results were reported, Perfuse Therapeutics had indicated plans to begin larger, late-stage trials in the second half of 2025. However, no phase 3 studies involving PER-001 are currently listed in public trial registries. Bayer confirmed that the program remains in phase 2 development, and its announcement did not specify a timeline for the next steps.
The acquisition represents Bayer’s largest deal since its 2020 purchase of AskBio, which was valued at up to $4 billion, according to The Wall Street Journal. Following that transaction, the company continued to pursue acquisitions, including Vividion Therapeutics for as much as $2 billion and KaNDy Therapeutics in a deal reaching almost $900 million. However, more recent deal activity had largely centered on early-stage programs that had not yet entered human testing, as noted by MarketWatch.
The company’s financial flexibility has been constrained in recent years by the $63 billion acquisition of Monsanto in 2018. That deal left Bayer with significant debt and ongoing legal challenges, which absorbed management focus and limited its ability to pursue large-scale transactions. According to The Wall Street Journal, these pressures kept the company relatively inactive in the M&A market while competitors continued to expand, even as key products like Xarelto and Eylea lost patent protection.
Stefan Oelrich, who heads Bayer’s pharmaceutical unit, recently told The Wall Street Journal that the company is currently engaged in multiple ongoing deal discussions.
Bayer is strengthening its ophthalmology portfolio through the acquisition of Perfuse Therapeutics in a deal valued at up to $2.4 billion. The move reinforces Bayer’s commitment to expanding innovative treatments for serious eye diseases and advancing its long-term growth strategy in ophthalmology.
Bayer’s Acquisition of Perfuse Therapeutics
Bayer announced the acquisition as part of its broader effort to build a stronger pipeline of therapies targeting retinal and vascular eye diseases. Perfuse Therapeutics specializes in treatments designed to improve retinal blood flow and address underlying causes of vision impairment.
The global ophthalmology market has experienced rapid growth as age-related eye disorders become more common worldwide. Conditions such as diabetic retinopathy, glaucoma, retinal vein occlusion, and age-related macular degeneration are increasing due to aging populations and rising chronic disease rates.
Healthcare providers and pharmaceutical companies are prioritizing innovative treatments that not only slow disease progression but also preserve long-term vision and quality of life. This demand is driving substantial investment into advanced retinal therapies and vascular-focused treatment approaches.
Importance of Retinal Blood Flow Research
Many retinal diseases are linked to impaired blood circulation and vascular dysfunction within the eye. Reduced blood flow can damage delicate retinal tissues, leading to progressive vision loss and irreversible complications.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
